Finance

Lists
Why is CHRS down 8.04%?
Dive Deeper
CHRS:NASDAQ
Coherus Oncology Inc
$1.03
-8.04%
(-0.090) 1D
$1.03
+0.02% (+0.00020)
Pre-market
Closed: Oct 6, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHRS...
Open
$1.13
High
$1.13
Low
$1.01
Mkt. cap
164.82M
Avg. vol.
1.25M
Volume
6.25K
52-wk high
$2.62
52-wk low
$1.01
EPS
-$1.03
Beta
0.98
Shares outstanding
154.50M
No. of employees
144
Open
$1.13
High
$1.13
Low
$1.01
Mkt. cap
164.82M
Avg. vol.
1.25M
Volume
6.25K
52-wk high
$2.62
52-wk low
$1.01
EPS
-$1.03
Beta
0.98
Shares outstanding
154.50M
No. of employees
144
News stories
From web sources and news partners
About Coherus Oncology Inc
CEODennis Lanfear
Employees144
Founded2010
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websitecoherus.com
Analyst ratings
Based on 4 analysts giving stock ratings to CHRS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CHRS in the last 3 months.
Highest
Current $1.03
$10.00 (+870.87%)
Average
$7.75 (+652.43%)
Lowest
$4.00 (+288.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$7.00
+579.6%
09/21/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$4.00
+288.3%
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
$10.00
+870.9%
08/06/2026
Jay Olson
Oppenheimer
Buy
Maintained
$10.00
+870.9%
08/06/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
-
-
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.57M
12.75M
12.31M
14.31M
Cost of goods sold
3.72M
4.04M
3.81M
4.24M
Cost of revenue
3.72M
4.04M
3.81M
4.24M
Research and development expenses
27.25M
30.97M
21.54M
21.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22.83M
21.01M
23.10M
20.95M
Operating expense
50.08M
51.98M
44.65M
42.40M
Total operating expenses
53.80M
56.03M
48.46M
46.64M
Operating income
-42.23M
-43.28M
-36.15M
-32.33M
Other non operating income
2.14M
-5.22M
1.40M
1.31M
EBT including unusual items
-44.52M
-46.35M
-36.94M
-33.35M
EBT excluding unusual items
-42.42M
-43.75M
-36.94M
-33.35M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35.53M
-37.64M
-38.33M
-20.63M
Net profit margin
-307.07%
-295.29%
-311.35%
-144.20%
Earnings per share
-0.33
-0.34
-0.25
-0.19
Interest and investment income
-
7.00M
-
-
Interest expense
-2.32M
-2.25M
-2.19M
-2.32M
Net interest expenses
-2.32M
4.75M
-2.19M
-2.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.27M
-42.38M
-35.27M
-31.47M
Gain or loss from assets sale
-
-338.32M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps